Indian scientist find rare plant with potential anti-cancer properties

Image
IANS Bangalore
Last Updated : May 14 2015 | 3:07 PM IST

A team of Indian scientists has discovered in the Western Ghats a rare plant which could open up possibilities for cancer treatment.

The plant, with botanical name Miquelia dentate Bedd, is a small climbing shrub producing anti-cancer alkaloid -- Camptothecine (CPT). It occurs sparsely in Madikeri Forests in Kodagu in Karnataka, the researchers reported.

The team of scientists from Ashoka Trust for Research in Ecology and Environment, Bengaluru and University of Agricultural Sciences, Bengaluru and Dharwad, who found the plant is now working on its commercial cultivation.

"We plan to introduce this plant in coffee plantations and in arecanut gardens. We have been doing some experiments in this regard with some of the planters in collaboration with Forestry College Sirsi as well as University of Agricultural Sciences, Bengaluru," said one of the lead study authors G. Ravikanth.

"The challenge however is to mass multiply this plant," Ravikanth, fellow at Suri Sehgal Centre for Biodiversity and Conservation under Ashoka Trust for Research in Ecology and Environment, Bengaluru, noted.

Camptothecine is an important anti-cancer compound extracted from several plant species belonging to Asterid clade. It is a potent inhibitor of the intra-nuclear enzyme topoisomerase-I, which is required in DNA replication and transcription.

Several semi-synthetic drugs such as Hycamtin (topotecan) and Camptostar (irinotecan or CPT 11) are derived from CPT and are currently in clinical use against ovarian, small lung and refractory ovarian cancer.

"Our aim is to see that we (India) also produce in Campthothecine both for our own use as well as for the global market," Ravikanth noted.

Several plant species producing CPT have been found in India. But the demand for CPT has resulted in extensive felling of the woody trees and plants like Nothapodytes nimmoniana, which is now on the verge of extinction and declared vulnerable.

The findings were detailed in the latest edition of Indian Journal on Biotechnology.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 14 2015 | 3:00 PM IST

Next Story